Continuing with approaches like that adopted by Brownjohn and colleagues, developing hiPSC-derived microglia from patients with AD risk loci, such as those associated with CR1, PICALM and MEF2C, could extend our understanding of how these variants contribute to increased AD risk via both in vitro culture and in vivo chimeric analyses. This evidence concerns the gene CR1 and Alzheimer disease.